Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite recent advances in precision medicine and a significant increase in the number of available therapies, only 1 in 3 patients receiving therapy respond.
Elephas is solving this problem by developing a technology suite to assess how human live tumor fragments (hLTF)™ respond to cancer therapies. We are removing the trial-and-error approach to cancer care by harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence to accelerate drug development and empower clinical decision-making.
Our unique approach maintains the native 3-dimensional cellular architecture and micro-environment of the patient’s tumor, enabling rapid real-time profiling of live tumor samples with immuno-oncology agents, targeted therapies, chemotherapy, and cell therapies.
We have a group of highly talented people, all committed to delivering a transformative diagnostic solution and bringing hope to cancer patients worldwide. People truly come first to us and we are committed to building a company culture of inclusivity, empowerment, curiosity, generosity and fun.